Literature DB >> 29103560

Equine Glaucoma.

Tammy Miller Michau1.   

Abstract

Glaucoma is a multifactorial neurodegenerative ocular disease leading to progressive loss of retinal ganglion cells and their axons that form the optic nerve, causing blindness. Knowledge of the pathogenesis and development of equine glaucoma is in its infancy compared with human glaucoma. Glaucoma occurs most commonly secondary to uveitis and may be underdiagnosed or misdiagnosed in horses suffering from uveitis. Recognition and clinical diagnosis of glaucoma in the horse is improved with clinician awareness and the availability of handheld tonometers. Therapy for glaucoma is aimed at decreasing aqueous humor production through medical and surgical means. Even with therapy, long-term prognosis for vision is poor.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Equine; Glaucoma; Neurodegenerative; Surgery; Therapy; Tonometry

Mesh:

Year:  2017        PMID: 29103560     DOI: 10.1016/j.cveq.2017.07.005

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN: 0749-0739            Impact factor:   1.792


  4 in total

1.  Diagnostic Ophthalmology.

Authors:  Lynne S Sandmeyer; Marina Leis; Stephanie Osinchuk
Journal:  Can Vet J       Date:  2019-07       Impact factor: 1.008

2.  Comparison of two rebound tonometers in healthy horses.

Authors:  Minna P Mustikka; Elina M Pietilä; Anna K Mykkänen; Thomas S C Grönthal
Journal:  Vet Ophthalmol       Date:  2020-09-04       Impact factor: 1.644

3.  Retinal detachment secondary to vitreoretinopathy in two closely related warmblood horses.

Authors:  Eline Vercruysse; Carolina Naranjo; Aurélie Sauvage; Maxime Vandersmissen; Magda Grauwels; Sébastien Monclin
Journal:  Open Vet J       Date:  2021-11-19

4.  Clinical, ultrasonographic, and histopathologic findings in seven horses with Descemet's membrane detachment: A case series.

Authors:  Inge J M Slenter; Hanneke Hermans; Jos M Ensink; Dorien S Willems; Stefanie Veraa; Guy C M Grinwis; Michael H Boevé
Journal:  Vet Ophthalmol       Date:  2019-09-22       Impact factor: 1.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.